Cand.med. Gro Grimnes disputerer for ph.d.-graden i helsevitenskap og vil offentlig forsvare avhandlingen:
Kort sammendrag av avhandlingen:
Venous thromboembolism (VTE) is a serious disease affecting 1-2 per 1000 each year. Acute infection and other inflammatory conditions have been associated with VTE risk in previous studies, and we aimed to investigate aspects of the association between infection, inflammation, and VTE. We used data from the Tromsø Study and found no association between the inflammatory marker neutrophil to lymphocyte ratio and risk of future VTE after long-term follow-up. In a case-crossover study, we found that acute infection was a frequent and strong trigger for VTE in hospitalized patients, and that concomitant infection and immobilization had a synergistic effect on VTE risk. Acute inflammation, assessed by C-reactive protein (CRP), was associated with VTE risk, regardless of the cause of inflammation. In a randomized controlled trial we found that a Vancomycin-induced change in the gut microbiome was accompanied by increased levels of coagulation factor VIII:C and CRP. (Avhandlingen er tilgjengelig for utlån hos Seksjon for forskningstjenester frem til disputasdato)
Veiledere
Hovedveileder: professor John-Bjarne Hansen
Medveileder: førsteamanuensis Sigrid K Brækkan
Bedømmelseskomiteen
Professor Karina Meijer, Division of Haemostasis and Thrombosis, Department of Haematology University Medical Centre Groningen, Nederland– 1. opponent
Førsteamanuensis Ingvild Nordøy, Institutt for Klinisk Medisin, Universitetet i Oslo– 2. opponent
Professor Trond Flægstad, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet – leder av komité
Disputasleder
Professor Rolf Jorde, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet
Prøveforelesning over oppgitt emne holdes kl. 10.15, samme sted: “VTE treatment in the era of personalized medicine”